{"id":90030,"date":"2026-11-08T00:12:21","date_gmt":"2026-11-08T00:12:21","guid":{"rendered":"https:\/\/wallstreetresearch.org\/wsr\/?p=90030"},"modified":"2026-11-08T00:12:21","modified_gmt":"2026-11-08T00:12:21","slug":"pressure-biosciences-corporate-profile-2016","status":"publish","type":"wsr_report","link":"https:\/\/wallstreetresearch.org\/wsr\/research\/pressure-biosciences-corporate-profile-2016\/","title":{"rendered":"Pressure BioSciences, Inc.: Corporate Profile"},"content":{"rendered":"<p>Pressure BioSciences, Inc. (PBI), based in South Easton, Massachusetts, is a medical research products and technology company serving academic and government laboratories as well as biotechnology, pharmaceutical and other life sciences companies. It develops, markets and sells proprietary laboratory instruments and consumables for the life sciences sample preparation market, estimated at $6 billion, and had installed approximately 300 systems at about 160 sites worldwide.<\/p>\n<p>PBI&#8217;s technology platform is based on constant and alternating hydrostatic pressure (Pressure Cycling Technology, or PCT), which can help control the actions of molecules in biological samples. Its products include Barocycler instruments, the Shredder System and related consumables, and it held 14 U.S. and 10 foreign patents. In 2016 PBI introduced its redesigned Barocycler 2320EXTREME, signed a two-year co-marketing agreement with SCIEX, a subsidiary of Danaher, and sold instruments selected for the Cancer Moonshot initiative. It reported 22% product sales growth for the first nine months of 2016.<\/p>\n<p>OTCQB: PBIO \u00b7 Life sciences instruments<\/p>\n<p><a href=\"https:\/\/www.wallstreetresearch.org\/reports\/PBIO5_NOV_V4_FINAL.pdf\">Read the corporate profile (PDF, 1 pages)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A medical research products and technology company in South Easton, Massachusetts, serving academic and government laboratories and life sciences companies.<\/p>\n","protected":false},"author":1,"featured_media":0,"template":"","meta":{"wsr_company":"Pressure BioSciences, Inc.","wsr_report_label":"Corporate Profile","wsr_report_kind":"profile","wsr_report_url":"https:\/\/www.wallstreetresearch.org\/reports\/PBIO5_NOV_V4_FINAL.pdf","wsr_report_pages":"1","wsr_report_date":"2016-11-19","wsr_report_undated":"","wsr_report_date_shown":"November 19, 2016","wsr_listing":"OTCQB: PBIO","wsr_market":"otc","wsr_symbol":"PBIO","wsr_ticker":"PBIO","wsr_exchange":"OTCQB","wsr_industry":"Life sciences instruments","wsr_website":"","wsr_milestone":"","wsr_logo":"","wsr_cover_image":"cv-pbio.webp","wsr_featured":"","wsr_in_cards":"1","wsr_track":"1","wsr_track_priority":"2","wsr_track_tile":"","wsr_track_only":"","footnotes":""},"tags":[55,104],"class_list":["post-90030","wsr_report","type-wsr_report","status-publish","hentry","tag-biotech","tag-pressure-biosciences"],"_links":{"self":[{"href":"https:\/\/wallstreetresearch.org\/wsr\/wp-json\/wp\/v2\/wsr_report\/90030","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wallstreetresearch.org\/wsr\/wp-json\/wp\/v2\/wsr_report"}],"about":[{"href":"https:\/\/wallstreetresearch.org\/wsr\/wp-json\/wp\/v2\/types\/wsr_report"}],"author":[{"embeddable":true,"href":"https:\/\/wallstreetresearch.org\/wsr\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":1,"href":"https:\/\/wallstreetresearch.org\/wsr\/wp-json\/wp\/v2\/wsr_report\/90030\/revisions"}],"predecessor-version":[{"id":97058,"href":"https:\/\/wallstreetresearch.org\/wsr\/wp-json\/wp\/v2\/wsr_report\/90030\/revisions\/97058"}],"wp:attachment":[{"href":"https:\/\/wallstreetresearch.org\/wsr\/wp-json\/wp\/v2\/media?parent=90030"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wallstreetresearch.org\/wsr\/wp-json\/wp\/v2\/tags?post=90030"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}